Merck & Co Inc


Market Cap$320.66B

Compare MerckInc

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Merck & Co IncMerck & Co Inc69.62.32%11%5.60.8
marketMarket Avg49.51.28%13%6.20.1
HealthcareHealthcare Avg31.91.26%18%7.50.9

Earnings Call Q4 2023

February 1, 2024 - AI Summary

Merck reported strong revenue growth of 12% in 2023, driven by robust performance in oncology, vaccines, and animal health.
The company expects continued strong growth in 2024, with projected revenue between $62.7 billion and $64.2 billion, representing a growth rate of 4% to 7%.
Key products like KEYTRUDA and GARDASIL contributed to the revenue growth, with KEYTRUDA sales increasing by 22% to $6.6 billion.
Merck is anticipating FDA action on its application for sotatercept in pulmonary arterial hypertension, which has the potential to transform treatment options for patients.
The FDA has accepted for priority review Merck's filing for V116, a pneumococcal conjugate vaccine designed for adults. If approved, it could become an important preventative option for adults aged 65 and older.
Merck remains committed to its dividend and plans to increase it over time, while also prioritizing investments in business growth and pursuing science-driven business development opportunities.

Target Price by Analysts

2.1% upsideMerckInc Target Price DetailsTarget Price

Current Fair Value

1% upside

Undervalued by 1% based on the discounted cash flow analysis.

Share Statistics

Market cap$320.66 Billion
Enterprise Value$346.74 Billion
Dividend Yield$2.9297 (2.32%)
Earnings per Share$1.81
Outstanding Shares2,534,023,084
Avg 30 Day Volume7,786,403


Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio69.59
Price to Sales5.62
Price to Book Ratio8.08
Enterprise Value to Revenue5.85
Enterprise Value to EBIT36.44
Enterprise Value to Net Income75
Total Debt to Enterprise0.1
Debt to Equity0.85

Revenue Sources

No data

ESG Score

No data

About Merck & Co Inc

CEO: Kenneth Frazier